Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Kanamycin Sulfate

FDA-approved product (capsule, oral), marketed as Kanamycin, Kanamycin Sulfate, Kantrex and 1 more.

Registered studies
50+
Lab records
73
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Kanamycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antibiotics; Other aminoglycosides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB04; WHO ATC A07AA08; WHO ATC S01AA24

Repurposing investigation

Kanamycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis78.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 11 lab records
  • E. coli: measured active in 9 of 24 lab records
  • K. pneumoniae: measured active in 4 of 11 lab records
  • M. tuberculosis: measured active in 26 of 27 lab records
Open Kanamycin Sulfate in ChEMBL Registered studies below
Show the 73 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Kanamycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

    NCT01608555 · start 2012-01

    Registered record
    Registry ID
    NCT01608555
    Conditions
    Cystic Fibrosis
    Interventions
    tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventiontobramycin
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

    NCT01431326 · start 2011-11

    Registered record
    Registry ID
    NCT01431326
    Conditions
    Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
    Interventions
    The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2019-11
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 more
    InterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

    NCT01456780 · start 2011-08

    Registered record
    Registry ID
    NCT01456780
    Conditions
    Meibomian Gland Dysfunction; Posterior Blepharitis
    Interventions
    Loteprednol/tobramycin; Loteprednol; B+L Advanced Eye Relief Lubricant Drop
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2017-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeibomian Gland Dysfunction; Posterior Blepharitis
    InterventionLoteprednol/tobramycin; Loteprednol; B+L Advanced Eye Relief Lubricant Drop
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis

    NCT01337219 · start 2011-04

    Registered record
    Registry ID
    NCT01337219
    Conditions
    Cystic Fibrosis
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2011-04
    Completion
    Not recorded
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobramycin
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

    NCT01227915 · start 2011-02

    Registered record
    Registry ID
    NCT01227915
    Conditions
    Acute Bacterial Conjunctivitis
    Interventions
    Tobracort; Tobradex
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-02
    Completion
    Not recorded
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Conjunctivitis
    InterventionTobracort; Tobradex
    PhasePhase 3
    Registry statusUnknown

  • Clinical Trials to Reduce the Risk of Antimicrobial Resistance

    NCT01570192 · start 2010-09

    Registered record
    Registry ID
    NCT01570192
    Conditions
    Bacterial Pneumonia
    Interventions
    IV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h; Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.; tobramycin nebulization
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2015-04
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionIV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h +3 more
    PhasePhase 2
    Registry statusTerminated

  • Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic

    NCT00950222 · start 2009-06

    Registered record
    Registry ID
    NCT00950222
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Imipenem/Amikacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-06
    Completion
    2012-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionImipenem/Amikacin
    PhaseNot applicable
    Registry statusCompleted

  • Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

    NCT00774072 · start 2008-10

    Registered record
    Registry ID
    NCT00774072
    Conditions
    Cystic Fibrosis; Pseudomonas Aeruginosa
    Interventions
    Tobramycin (Gernebcin®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pseudomonas Aeruginosa
    InterventionTobramycin (Gernebcin®)
    PhasePhase 2
    Registry statusCompleted

  • Tobramycin Tear Concentrations

    NCT00695435 · start 2008-06

    Registered record
    Registry ID
    NCT00695435
    Conditions
    Dry Eye
    Interventions
    TOBRADEX Ophthalmic Suspension; Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension; TOBREX Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    Not recorded
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionTOBRADEX Ophthalmic Suspension; Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension; TOBREX Ophthalmic Solution
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

    NCT00705159 · start 2008-06

    Registered record
    Registry ID
    NCT00705159
    Conditions
    Conjunctivitis
    Interventions
    loteprednol etabonate and tobramycin; loteprednol etabonate; Tobramycin; Vehicle of Zylet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-05
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis
    Interventionloteprednol etabonate and tobramycin; loteprednol etabonate; Tobramycin; Vehicle of Zylet
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

    NCT00634192 · start 2008-02

    Registered record
    Registry ID
    NCT00634192
    Conditions
    Pseudomonas Infections
    Interventions
    tobramycin; tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudomonas Infections
    Interventiontobramycin; tobramycin
    PhasePhase 3
    Registry statusCompleted

  • TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

    NCT00576251 · start 2007-10

    Registered record
    Registry ID
    NCT00576251
    Conditions
    Ocular Inflammation Associated With Blepharaconjunctivitis
    Interventions
    Tobramycin 0.3%/Dexamethasone 0.05%; TOBRADEX
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Inflammation Associated With Blepharaconjunctivitis
    InterventionTobramycin 0.3%/Dexamethasone 0.05%; TOBRADEX
    PhasePhase 3
    Registry statusCompleted

  • Antiseptic Use and Dressing Application

    NCT00389558 · start 2006-09

    Registered record
    Registry ID
    NCT00389558
    Conditions
    Skin Colonization; Catheterization; Bacterial Infection
    Interventions
    disinfection efficacy using Biseptine; disinfection efficacy using Amukin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2008-10
    Enrolment
    453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Colonization; Catheterization; Bacterial Infection
    Interventiondisinfection efficacy using Biseptine; disinfection efficacy using Amukin
    PhasePhase 4
    Registry statusCompleted

  • A Bioequivalence Study of Tobradex AF

    NCT00362895 · start 2006-04

    Registered record
    Registry ID
    NCT00362895
    Conditions
    Cataract
    Interventions
    Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension; Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2006-08
    Enrolment
    995

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionTobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension; Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
    PhasePhase 3
    Registry statusCompleted

  • Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia

    NCT00786305 · start 2004-10

    Registered record
    Registry ID
    NCT00786305
    Conditions
    Pneumonia
    Interventions
    ceftazidime and amikacin; ceftazidime and amikacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-10
    Completion
    2008-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    Interventionceftazidime and amikacin; ceftazidime and amikacin
    PhasePhase 2
    Registry statusCompleted